Originally published In Press as doi:10.1074/jbc.M110638200 on January 17, 2002
J. Biol. Chem., Vol. 277, Issue 16, 13943-13951, April 19, 2002
The Streptococcal Hyaluronan Synthases Are Inhibited by
Sulfhydryl-modifying Reagents, but Conserved Cysteine Residues Are Not
Essential for Enzyme Function*
Kshama
Kumari,
Valarie L.
Tlapak-Simmons,
Bruce A.
Baggenstoss, and
Paul H.
Weigel
From the Department of Biochemistry and Molecular Biology,
University of Oklahoma Health Sciences Center,
Oklahoma City, Oklahoma 73190
Received for publication, November 6, 2001, and in revised form, January 15, 2002
 |
ABSTRACT |
Hyaluronan (HA) synthase (HAS) is a
membrane-bound enzyme that utilizes UDP-glucuronic acid (GlcUA) and
UDP-GlcNAc to synthesize HA. The HAS from Streptococcus
pyogenes (spHAS, 419 amino acids) contains six Cys residues,
whereas the enzyme from Streptococcus equisimilis (seHAS,
417 amino acids) contains four Cys residues. These Cys residues of
seHAS are highly conserved in all Class I HAS family members. Here we
investigated the structural and functional roles of these conserved
cysteines in seHAS by using site-directed mutagenesis and sensitivity
to sulfhydryl modifying reagents. Both seHAS and spHAS were inhibited
by sulfhydryl reagents such as N-ethylmaleimide (NEM) and
iodoacetamide in a dose-dependent and
time-dependent manner. These inhibition curves were
biphasic, indicating the presence of sensitive and insensitive
components. After treatment of seHAS with NEM, the
Vmax value was decreased ~50%, and the
Km values changed only slightly. All the Cys-to-Ala
mutants of seHAS were partially active. The least active single
(C226A), double (C226A,C262A), or triple (C226A,C262A,C367A) Cys
mutants retained 24, 3.2, and 1.4% activity, respectively, compared
with wild-type enzyme. Surprisingly, the Vmax
value of the seHAScys-null mutant was ~17% of wild-type,
although the Km values for both substrates were
increased 3-6-fold. Cys residues, therefore, are not involved in a
critical interaction necessary for either substrate binding or
catalysis. However, the distribution of HA products was shifted to a
smaller size in ~25% of the seHAS Cys mutants, particularly the
triple mutants. Mass spectroscopic analysis of wild-type and Cys-null
seHAS as well as the labeling of all double Cys-to-Ala mutants with
[14C]NEM demonstrated that seHAS contains no disulfide
bonds. We conclude that the four Cys residues in seHAS are not directly involved in catalysis, but that one or more of these Cys residues are
located in or near substrate binding or glycosyltransferase active
sites, so that their modification hinders the functions of
HAS.
 |
INTRODUCTION |
HAS1 is a membrane-bound
enzyme that catalyzes the synthesis of HA in both eukaryotes and
prokaryotes. HA is a linear hetero-polysaccharide consisting of
repeating (GlcUA
(1,3)-GlcNAc
(1,4)) disaccharide units (1, 2).
HA is a ubiquitous component of extracellular matrices in vertebrates.
This glycosaminoglycan is present in large amounts to serve specialized
functions in cartilage, synovial fluid, dermis, and the vitreous humor
of the eye (1-4). HA plays critical roles during fertilization and
embryogenesis as well as development and differentiation. In many Group
A and Group C streptococcal strains, HA forms a capsule that helps
these pathogens evade the host immune system during infection (5-7).
Substantial progress in understanding HA biosynthesis has been made
since the first cloning in 1993 of a HAS from the human pathogen Group A Streptococcus pyogenes (8). Other members of the same HAS family were subsequently identified and cloned from human, mouse, frog,
cow, rabbit, and chicken (9-16) and also from prokaryotes, including
an algal-specific virus (17), Group C Streptococcus equisimilis (18), the bovine pathogen Streptococcus
uberis (19), and the fowl pathogen Pasteurella
multocida (20). With the exception of the latter enzyme, which has
been designated the only member of the Class II HAS family (14), all of
the Class I HASs from prokaryotes and eukaryotes are ~28-30%
identical and are predicted to share a common membrane topology (21,
22). The three streptococcal HAS genes and protein sequences are
70-75% identical.
Although HAS functions as a glycosyltransferase, it is different from
the vast majority of previously characterized enzymes in that it is a
dual transferase with at least six different functions (23, 24). The
single HAS polypeptide binds both UDP-GlcNAc and UDP-GlcUA and
transfers these two different precursor sugars to the growing HA chain
(the bound acceptor) via two different linkages. In addition to these
five discrete substrate binding or catalytic functions, HAS is able to
extrude or translocate the growing HA chain into the extracellular
space while it remains bound to the enzyme at the plasma membrane (25,
26).
Two recombinant prokaryotic HASs, spHAS and seHAS, have been purified
and characterized kinetically (24, 27). All recombinant HASs, either
from vertebrates or prokaryotes, have been shown to synthesize high
molecular weight HA in vitro. The Class I HAS proteins
likely have essentially identical topological organizations in their
N-terminal regions that are highly homologous with spHAS, the only HAS
whose membrane topology has been determined experimentally (22).
In the present study we investigated the possibility that one or more
of the conserved Cys residues in seHAS may be necessary for one of the
six discrete HAS functions. Beginning in the 1950s almost all studies
of prokaryotic or eukaryotic HAS function have used isolated membranes,
in part because most of the eukaryotic HAS enzymes cannot be
detergent-solubilized with retention of activity. Therefore, we
performed a combination of site-directed mutagenesis, chemical
modification, and kinetic analyses using isolated membranes to
characterize the structural and functional role(s) of Cys in seHAS.
 |
EXPERIMENTAL PROCEDURES |
Vectors, Primers, and Reagents--
The expression vector pKK223
was from Amersham Biosciences, Inc.. Escherichia coli SURE
cells were from Stratagene. The QuikChangeTM site-directed
mutagenesis kit was obtained from Stratagene. All of the mutagenic
oligonucleotides were synthesized by Genosys Biotechnologies, Inc.
(Spring, TX) and were purified by reverse-phase chromatography. Cy-5
fluorescent sequencing primers were synthesized by the Molecular
Biology Resource Facility, Oklahoma University Health Sciences Center.
Other oligonucleotide primers were synthesized by The Great American
Gene Co. (Ransom Hill Bioscience, Inc., CA). UDP-GlcUA and UDP-GlcNAc
were from Fluka and Sigma, respectively. UDP-[14C]GlcUA
(300 mCi/mmol) and [14C]NEM (40 mCi/mmol)were from
PerkinElmer Life Sciences. NEM and biotin-PEO-maleimide were from
Sigma. All other reagents were the highest grade available from Sigma
unless otherwise noted.
Site-directed Mutagenesis--
The seHAS gene with a fusion at
the 3' end encoding a His6 tail (seHAS-His6)
was cloned into pKK233 as described earlier (27). Mutagenic primers
were designed to change the cysteines to either Ala or Ser at positions
226, 262, 281, and 367. Two complementary oligonucleotide primers
encoding the desired mutation were used to create the single Cys
mutations (Table I). Mutagenesis was carried out using the QuikChange method according to the
manufacturer's instructions. The pKK233 plasmid containing the
seHAS-His6 gene was grown in SURE cells, purified using a
Spin Miniprep kit (Qiagen), and analyzed by agarose gel electrophoresis
to verify the correct size. The purified pDNA was used as the template
for the primer extension reaction with a pair of mutagenic primers. The
PCR amplification conditions for PCR, using Pfu DNA
polymerase, were 16 cycles of the following: 95 °C for 1 min,
58 °C for 1 min, and 68 °C for 18 min. This amplification
generated mutated plasmids with staggered nicks, which were then
treated with DpnI to digest the methylated and
hemi-methylated parental DNA. The digested pDNA was transformed into
SURE cells, and colonies were screened for the desired mutations by
sequencing the isolated plasmid DNA using fluorescently labeled terminators (ABI Prism 377 MODEL program, v2.1.1). The complete open
reading frames of selected mutants were confirmed by sequencing in both
directions with Cy-5-labeled vector primers on a Amersham Biosciences,
Inc. ALF Express DNA Sequencer. Data were analyzed using ALF Manager,
v3.02. The double, triple, and null Cys mutants of
seHAS-His6 were made using the appropriate single, double, or triple Cys mutant plasmid DNA as the template, respectively.
View this table:
[in this window]
[in a new window]
|
Table I
Synthetic oligonucleotides used to make seHAS mutants
The boldface font indicates the altered codon. All primers shown are in
the sense orientation.
|
|
Effect of Sulfhydryl Reagent Treatments on seHAS and spHAS
Activity and Determination of the Kinetic Constants of seHAS Cys
Mutants--
E. coli SURE cells transformed with plasmids
containing various seHAS mutants were grown in LB medium with vigorous
shaking at 32 °C to a A600 ~ 0.8 and
induced with 1 mM isopropyl-
-thiogalactoside for 3 h. Cells were harvested, and membranes were prepared as described
previously (28). The initial activities for HAS were determined at
37 °C in 100 µl of 50 mM sodium and potassium
phosphate, pH 7.0, with 20 mM MgCl2, 1 mM DTE, 240 µM UDP-GlcUA, 0.7 µM UDP-[14C]GlcUA, and 0.6-1.0
mM UDP-GlcNAc. The kinetic constants for both UDP-GlcUA and
UDP-GlcNAc were determined in 100 µl of 25 mM sodium and
potassium phosphate, pH 7, containing 50 mM NaCl, 20 mM MgCl2, 1 mM dithiothreitol, 0.7 µM UDP-[14C]GlcUA, and various amounts of one
substrate (0.01-4 mM) while holding the other constant at
1 mM. Some assays also contained 0.1 mM EDTA
and 20% glycerol (v/v). To initiate the enzyme reaction, ~0.5-40
µg of membrane protein was added, and the mixtures were gently shaken
in a MicroMixer X-36 (Taitec) at 30 °C for 1-2 h. The reactions
were terminated by the addition of SDS to a final concentration of 2%
(w/v). The incorporation of radioactive [14C]GlcUA was
determined by descending paper chromatography, and the
Km and Vmax values were
determined as described by Tlapak-Simmons et al. (24). Data
were analyzed by the methods of Michaelis-Menten (29) or Hill (30). The
protein content was determined by the method of Bradford (31) using
bovine serum albumin as the standard. All Cys mutant or
sulfhydryl-treated seHAS samples were assayed in duplicate or
triplicate using two or three independent membrane preparations. The
results are presented as the mean ± S.E. All enzyme assays were
performed under conditions that were linear with respect to time and
protein concentration. None of the seHAS variant enzymes were unstable
under the conditions employed.
Determination of HA Size Produced by seHAS Variants--
The
relative Mr of the HA synthesized by wild-type
seHAS or the Cys mutants was determined by agarose gel electrophoresis (32) of 14C-labeled HA products synthesized under the assay
conditions described above. The wild-type seHAS synthesizes and
releases an HA chain in <5 min under these steady-state conditions
(18) so that each enzyme molecule on average synthesizes >10 HA chains
during the incubation. The reactions were terminated by heating at
95 °C for 1 min, the mixtures were then centrifuged at high speed,
and the HA-containing supernatants were recovered. The samples were concentrated ~10-fold using Microcon YM-3 filters (Amicon
Bioseparations, Inc.) and treated with DNase and RNase (4 µg/ml each)
in the presence of 60 mM MgCl2 for 30 min at
22 °C. The samples and a combination of DNA standards were then
electrophoresed on a 1.3% (w/v) agarose gel at 80-90 V. The gels were
dried without heating and exposed to Biomax-MR film (Eastman Kodak Co.)
for 1-4 weeks. The autoradiograms were scanned to create digital files
using a FluorchemTM8000 (Alpha Innotech Corp.) image
analysis station. As a control, samples were treated with
Streptomyces hyaluronate lyase (80 units) at 37 °C
overnight, which resulted in the complete loss of radiolabeled bands.
Determination of seHAS Protein Concentration in Membranes and
Normalization of seHAS Activity--
The recombinant seHAS protein in
isolated membranes is a major component comprising ~5-8% of the
total protein, is well separated from other major proteins by SDS-PAGE,
and can be readily identified in Coomassie Blue-stained gels (18).
E. coli membranes containing wild-type or mutant seHASs were
solubilized and electrophoresed on 10% (w/v) gels following the
procedure of Laemmli for SDS-PAGE (33). The amount of seHAS protein in
each membrane preparation was quantitated by image analysis of the
stained gel using a FluorchemTM8000 (Alpha Innotech Corp).
The linearity of Coomassie Blue-stained seHAS bands was verified by
loading different amounts of membrane protein. To generate a standard
curve, various amounts of affinity-purified seHAS-His6 were
subjected to identical SDS-PAGE, and the integrated density value was
determined for each band. The integrated density values were plotted
against pmol of pure seHAS (e.g. see Fig. 1 in Ref. 22). The
integrated density value values for seHAS bands in membranes containing
wild-type or mutant proteins were then compared with the standard to
estimate the seHAS protein content per mg of membrane protein. These
data were then used to normalize the seHAS enzyme activity in the
membrane preparations for wild-type and each variant seHAS.
Chemical Modification of HAS in Membranes--
Stock solutions
(10-100 mM) of NEM, iodoacetamide, or other sulfhydryl
reagents were made in PBS, pH 7.0. Suspensions of membranes containing
seHAS or spHAS were incubated with 0-5 mM sulfhydryl reagent at 4 °C, and the reactions were stopped by adding DTE to a
final concentration of 10 mM. The membranes were then
assayed for HAS activity as described above.
Labeling of seHAS with [14C]NEM--
Isolated
membranes from wild-type seHAS and each of the six double Cys mutants
of seHAS were incubated at 4 °C with 2.5 mM [14C]NEM (~8 × 106 dpm) for 5 min.
The reactions were terminated by the addition of DTE to a final
concentration of 5 mM. Total membrane proteins were
precipitated by incubation with 10% trichloroacetic acid overnight at
4 °C, and free [14C]NEM was then removed by two cycles
of centrifugation and resuspension with 5% trichloroacetic acid. The
precipitated proteins were dissolved in 1× SDS Laemmli sample buffer
(33), neutralized by the addition of 0.1 N NaOH, and
analyzed by SDS-PAGE using a 10% gel. The Coomassie Blue-stained gel
was scanned using a model PDSIP60 densitometer (Molecular Dynamics)
then treated with scintillants and subjected to fluorography using
Biomax-MR (Kodak) film and an exposure of ~1 week. E. coli
membranes prepared from cells transformed with vector alone, containing
no seHAS, were included as a control.
MALDI-TOF Analysis of seHAS Derivatives--
As previously
described (27), wild-type seHAS-His6 was bound to a
Ni+2-nitrilotriacetic acid chelate resin (Qiagen), washed,
and treated with biotin-PEO-maleimide (10 mg/ml) for 2 h on ice.
After washing the column, the enzyme was eluted with distilled water
containing 0.5% (v/v) trifluoroacetic acid and 0.02% (w/v)
dodecylmaltoside. The degree of modification of Cys residues in treated
seHAS samples was determined using a MALDI-TOF Voyager Elite mass
spectrometer (Applied Biosystems, Framingham, MA) that was equipped
with a N2 laser (337 nm), located in the National Science
Foundation EPSCoR Oklahoma Laser Mass Spectrometry Facility. The
sample (1 µl) was spotted to a sample plate followed by matrix
solution (1 µl) and allowed to air dry. The matrix used was a 20 mg/ml solution of 2,4,6-trihydroxyacetophenone in 50% acetonitrile
containing 0.1% trifluoroacetic acid and 0.05% (w/v)
dodecylmaltoside. Samples were analyzed in the linear, positive ion
mode using a delayed extraction of 300 ns and a grid voltage of 87.8%
and were subject to a 25 kV accelerating voltage. External and internal
calibrations were routinely performed using horse apomyoglobin and
bovine serum albumin (16,951 and 66,430 Da, respectively). Spectra were
an average of 80-120 scans and were processed using the 19-point Savitsky-Golay smoothing option included in the software provided by
the manufacturer.
 |
RESULTS |
Sulfhydryl Reagents Inhibit the Activity of seHAS and
spHAS--
SeHAS is the smallest HAS protein (417 amino acids) and
contains four Cys residues. The four cysteines of seHAS are completely conserved among the three prokaryotic HASs (excluding P. multocida HAS) and are conserved positionally among all the
vertebrate HASs (Fig. 1). To explore the
possible role of cysteines in the function of HAS, the activities of
seHAS and spHAS were assayed in the presence of different sulfhydryl
reagents (Table II). Almost
identical sensitivities were observed for the two enzymes. For
example, seHAS activity was inhibited >93% by
methylmethanethiosulfonate (0.05 mM) and ~70% by NEM (5 mM), whereas iodoacetamide inhibited only 15%. Sodium
arsenite and 5,5'-dithiobis-(2-nitrobenzoic acid) also inhibited each
HAS activity. These results indicate that one or more Cys residues are
important for the overall HA synthesis activity of the seHAS and spHAS
proteins. The inhibition of each HAS by NEM was examined in more detail
with respect to the time of incubation and NEM concentration (Fig.
2). Both seHAS and spHAS were inhibited
in a biphasic manner with respect to incubation time or NEM
concentration. Although the extent of inhibition varied from experiment
to experiment, a 60-70% effect was typical. About half of the
observed inactivation occurred at
1 mM NEM, whereas the
remaining inactivation occurred from 1 to 6 mM (Fig.
2A). Kinetically, there was a fast initial inactivation and
then a much slower phase of inhibition; again, each of the phases
involved about half of the affected activity (Fig. 2B). A
potential complication in the above NEM studies is that the effects of
a sulfhydryl-modifying reagent could be due to secondary effects caused
by modification of other molecules in the membranes being tested.
Although this possibility is highly unlikely since seHAS is the only
protein necessary for HA biosynthesis (21, 27), we also examined the effect of sulfhydryl reagents on the seHAS Cys-null mutant in isolated
membranes under the conditions shown in Fig.
3. The activity of
seHASCys-null was not affected (
1%) by treatment with
NEM, iodoacetamide, or sodium arsenite, which eliminates the
possibility that modified secondary proteins in the membranes
preparations were responsible for the altered HAS activity.

View larger version (100K):
[in this window]
[in a new window]
|
Fig. 1.
General conservation of four cysteines in
seHAS within the Class I HAS protein family. The HAS protein
sequences (and their accession numbers) shown are: seHAS
(AAB87874); S. uberis (suHAS, CAB46918);
spHAS (AAA17981); chicken (ggHAS2, AF106940_1);
mouse (mmHAS1, BAA11654; mmHAS2, AAC53309;
mmHAS3, AAC53128); human (hsHAS1, NP_001514;
hsHAS2, NP_005319; hsHAS3, AF232772_1); rabbit
(ocHAS2, BAB63264; ocHAS3, BAB63265); bovine
(btHAS2, CAA06239); rat (rnHAS2, NP_037285);
chlorella virus (cvHAS2, AF113757_1); and frog
(xlHAS1, AF106940). The sequences were aligned using the
DNAsis multiple alignment program (v4.0). Cys residues including
the four in seHAS that are conserved in all three streptococcal enzymes
are in red and boldface. The bars
highlight the sequence regions of these four conserved Cys residues
within the larger HAS family. Residues that are identical in the three
HASs and in some of the other family members are highlighted in
gray. Residues in seHAS conserved among all other HAS family
members are highlighted in yellow. Conserved residues that
are within the active sites of all -glycosyltransferases are
indicated by a dot (21).
|
|
View this table:
[in this window]
[in a new window]
|
Table II
Effect of different sulfhydryl reagents on seHAS or spHAS activity
E. coli membranes expressing the recombinant
seHAS-His6 or spHAS-His6 proteins were incubated at
4 °C for 1 h with PBS containing either 5 mM NEM, 5 mM iodoacetamide, 0.5 mM
5,5'-dithiobis-(2-nitrobenzoic acid), 0.05 mM
methylmethanethiosulfonate, 10 mM sodium arsenite, or no
addition (control). The remaining seHAS activity was then determined in
quadruplicate. The mean values and S.D. are shown. The inhibition of
HAS activity is expressed as percent relative to the controls.
|
|

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 2.
Effect of NEM concentration and incubation
time on the activity of seHAS and spHAS. A, E. coli membranes containing recombinant seHAS or spHAS were
incubated at 4 °C for 1 h with PBS alone (minus NEM control) or
PBS containing different concentrations of NEM. The unreacted NEM was
quenched by the addition of DTE to a final concentration of 1-6
mM, and the samples were assayed for HAS activity as
described under "Experimental Procedures." B, the effect
of incubation time on seHAS and spHAS activity was assessed by
incubating the membranes with 5 mM NEM at 4 °C for the
indicated times. Aliquots were removed into assay buffer containing 5 mM DTE, and HAS activities were determined. HAS activity in
control untreated membranes was stable for 1 h at 4 °C. The
inhibition of HAS activity is expressed as percent relative to the
controls.
|
|

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 3.
Effect of NEM or sodium arsenite treatment on
the utilization of UDP-GlcUA and UDP-GlcNAc by wild-type seHAS.
E. coli membranes containing seHAS protein were incubated at
4 °C for 1 h in PBS containing 5 mM NEM or 10 mM sodium arsenite, and the control membranes were
incubated with PBS alone. Michaelis-Menten constants
(Km) were calculated from the activities of seHAS at
varying concentrations of UDP-GlcUA or UDP-GlcNAc.
|
|
Modification of the protein by NEM could affect any one or several of
the six discrete functions that HAS must perform to synthesize HA (23,
24). To determine whether one of the nucleotide-sugar binding sites was
affected by NEM, we examined the UDP-GlcUA and UDP-GlcNAc saturation
profiles for treated and untreated seHAS (Fig. 3 and Table
III). The Km values
for either UDP-GlcNAc (Fig. 3A) or UDP-GlcUA (Fig.
3B) were not altered significantly by treatment with NEM or
sodium arsenite, whereas the maximum enzymatic velocity was reduced by
up to ~70%.
View this table:
[in this window]
[in a new window]
|
Table III
Effect of NEM or sodium arsenite treatment on the utilization of
UDP-GlcUA and UDP-GlcNAc by wild-type seHAS
E. coli membranes containing seHAS protein were incubated at
4 °C for 1 h with PBS alone (control) or PBS containing 5 mM NEM or 10 mM sodium arsenite. The activity
of seHAS was determined in triplicate with varying concentrations of
UDP-GlcUA or UDP-GlcNAc as described under "Experimental
Procedures," and the Michaelis-Menten constants
(Km and Vmax) ± S.E. were
calculated.
|
|
Effect of Site-specific Cys Mutagenesis on the HA Synthase Activity
of seHAS--
Site-specific Cys-to-Ala and Cys-to-Ser mutants of seHAS
were made to explore the possible functional role of each Cys residue in HAS activity. In all of the following kinetic studies using the
wild-type and mutant seHAS proteins, the data obtained were normalized
to the amount of intact seHAS protein, as described under
"Experimental Procedures." The single Cys-to-Ala or Cys-to-Ser mutants of seHAS had lower enzyme activities compared with the wild-type enzyme except for the C367A and C367S variants (Fig. 4 and Table
IV). This result indicates that
Cys226, Cys262, and Cys281 may
contribute to the catalytic activity of seHAS in some way. The
Km values for UDP-GlcUA of the C226A and C262A
mutants were higher when compared with the corresponding values for the C226S and C262S variants. However, the Km values for UDP-GlcNAc were not quite as clear-cut. The
KUDP-GlcNAc value for the C226S mutant was
higher than that of the C226A mutant, whereas the C262A and C281A
mutant proteins both had higher KUDP-GlcNAc values compared with the C262S and C281S variants. At the
Cys367 position, similar Km values for
each nucleotide-sugar were obtained for both the Ala and Ser
mutants.

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 4.
Relative enzyme activities of the Cys-to-Ala
or Cys-to-Ser single Cys mutants of seHAS. Membranes from E. coli (SURE) cells expressing either wild-type seHAS or the
indicated single Cys mutants of seHAS were assayed for HAS activity
under linear conditions with respect to time and protein concentration,
and the amount of HAS protein expressed in each membrane preparation
was determined as described under "Experimental Procedures." The
normalized seHAS specific activities were calculated as nmol of
UDP-GlcUA incorporated per pmol of HAS per h. The specific activities
of seHAS mutants are given as a percent relative to wild-type activity
as 100%.
|
|
View this table:
[in this window]
[in a new window]
|
Table IV
Michaelis-Menten constants for single Cys-Mutants of seHAS
Kinetic analyses were performed as described under "Experimental
Procedures" using membranes prepared from E. coli SURE
cells expressing the indicated seHAS variants. Hill numbers for the
wild-type seHAS and single Cys mutants of seHAS ranged from 0.9 to 1.2, and none of the mutant values were significantly different from wild
type.
|
|
From the above results we conclude that functional constraints are put
on the enzyme by particular alterations of some of its Cys residues.
Because the C226A and C226S mutants were the least active,
Cys226 may be the most important Cys residue for enzyme
activity. The seHAS(C367A) variant was actually more active than
wild-type (~145%), and the seHAS(C367S) variant was not
significantly altered. In each of the four cases, the Cys-to-Ala change
resulted in a variant with greater activity than the Cys-to-Ser change.
The least tolerated single Cys change was C226S; this mutant was
inhibited >90%.
We next constructed and examined all the possible Cys-to-Ala
double mutants (C226A,C262A; C226A,C281A; C226A,C367A; C262A,C281A; C262A,C367A; C281A,C367A) as well as the triple mutants and the Cys-null mutant. For simplicity, we designate the triple Cys mutants by
a convention that indicates which of the four Cys residues remains
unaltered. For example, the triple mutant containing C226A,C281A,C367A changes is seHAS(
3C)C262, which has only one Cys at
position 262 as in the wild-type protein. The HA synthase activities of
these multiple-Cys seHAS mutants were then determined under saturating
conditions for each substrate and normalized to the amount of seHAS
protein present in the isolated membranes (Fig.
5). The least active double mutant was
C226A,C262A, which had only 2-3% of the specific activity of the
wild-type enzyme. All three double mutants in which Cys226
was changed to Ala had lower activity compared with the other three
double mutants. Two of the triple mutants, seHAS(
3C)C226
and seHAS(
3C)C262, were significantly more active
(~3-30-fold) than the other two triple mutants,
seHAS(
3C)C281 and seHAS(
3C)C367.

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 5.
Relative enzyme activities of the Cys-to-Ala
multiple Cys mutants of seHAS. Membranes expressing wild-type
seHAS, the indicated multiple Cys mutants of seHAS, or the
seHASCys-null were assayed and normalized as described in
Fig. 4.
|
|
Surprisingly, the Cys-null seHAS mutant was more active than the two
least active triple Cys mutants and two of the six double Cys mutants
(Fig. 5). The decreased activities of the single and multiple Cys
mutants are consistent with the inhibition of seHAS or spHAS by
sulfhydryl reagents described above. Based on the lower specific
activities of most of these Cys mutants, we conclude that no particular
cysteine residue in seHAS is required for a critical step during HA
synthesis. Nonetheless, these data also support the conclusion that
Cys226 and Cys262 may play a role in or at
least influence one or more of the six sub-activities required for the
overall activity of HAS. At least the alteration or modification of
these latter two residues hinders the enzyme and results in apparently
lower Vmax values.
Enzymatic Analysis of seHAS Cys Mutants--
To determine which
sub-activities of seHAS might be altered by mutating its Cys residues,
we performed kinetic analyses of the wild-type enzyme and all the Cys
mutants and calculated their respective Km and
Vmax values (Tables
IV-VI). A
comparison of the Vmax values for each of the
single, double, and triple Cys-to-Ala mutants of seHAS verified that
the two least active mutants were C226A,C262A and
seHAS(
3C)C281, with only ~1-3% of the wild-type
activity (as suggested by the results in Fig. 5). The seHAS(C226S)
mutant had ~10% of the wild-type activity (Table IV). The C226A,
seHAS(
3C)C367, C226A,C367A, and Cys-null mutants had
activities between 17 and 30% of wild-type. The remaining eight seHAS
Cys mutants retained 40% or more of the activity of wild-type seHAS.
The only mutant (Table IV) that had a higher activity than wild-type
was seHAS(C367A).
View this table:
[in this window]
[in a new window]
|
Table V
Michaelis-Menten constants for double Cys mutants of seHAS
Kinetic analyses were performed as described under "Experimental
Procedures" using membranes prepared from E. coli SURE
cells expressing the indicated seHAS variants.
|
|
View this table:
[in this window]
[in a new window]
|
Table VI
Michaelis-Menten constants for triple and quadruple Cys-mutants of
seHAS
Kinetic analyses were performed as described under "Experimental
Procedures" using membranes prepared from E. coli SURE
cells expressing the indicated seHAS variants.
|
|
The Km values for UDP-GlcUA for all the Cys mutants
(Tables IV-VI) differed by no more than 2-3-fold from wild-type seHAS. For most of the Cys mutants, the Km values
for UDP-GlcNAc also did not change dramatically (within 1-3-fold). These relatively modest changes indicate that the altered Cys residues in these seHAS variants play a relatively minor role in
how the enzyme binds and uses each nucleotide-sugar. However, some
combinations of Cys mutations had more dramatic effects on UDP-GlcNAc utilization. For example, the
KUDP-GlcNAc value for seHAS(
3C)226 was ~4-fold higher (Table VI). The
KUDP-GlcNAc values for the C226A,C262A mutant
(Table V) and the seHAS(
3C)C281,
seHAS(
3C)C367, and Cys-null mutants (Table VI) were even
more affected; they were ~6-9-fold more than wild-type. These latter
mutants were clearly less efficient in their utilization of UDP-GlcNAc
than the wild-type seHAS. Interestingly, these mutants also had Hill numbers >1.5, compared with a value of 1.0 for the wild-type enzyme, indicating that they had acquired a new level of cooperativity in their
utilization of UDP-GlcNAc. All of the above kinetic results indicate a
potentially important, although not absolutely essential, role for
Cys226 and Cys262 in seHAS activity.
Relative Size Distributions of HA Synthesized by Various Cys
Mutants of seHAS--
HASs from different species synthesize HA
products with a characteristic and often different distribution of
sizes. To determine whether any of the Cys mutants of seHAS synthesize
HA having an altered size distribution compared with wild-type seHAS,
we used agarose gel electrophoresis to fractionate the radiolabeled HA products made by each variant enzyme (Fig.
6). The majority of the single (Fig.
6A) and double Cys mutants (Fig. 6B) synthesized HA of essentially identical size compared with the wild-type enzyme. The C281A and C367S single mutants and the C262A,C281A and C281A,C367A double mutants made smaller products. Three of the four triple mutants
(all except seHAS(
3C)C281) and the Cys-null mutant made
smaller HA products (Fig. 6B). The smallest relative HA size
distribution was made by the triple mutant
seHAS(
3C)C226. Interestingly, the HA size distributions
of the seHAS mutants C226S, C226A,C262A, and (
3C)C281
were similar to that of the wild-type enzyme, even though these mutants
had the lowest activity (1.4-8% wild-type) and, therefore, the lowest
HA elongation rates. Overall, these results clearly show that mutations
of various combinations of Cys residues cause seHAS to synthesize
shorter HA chains than the wild-type enzyme, indicating that Cys
residues can influence the HA size distribution made by seHAS.

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 6.
Relative sizes of HA synthesized by wild-type
seHAS and the Cys mutants of seHAS. E. coli membranes
containing wild-type (WT) or the 19 Cys-mutants of seHAS
were incubated with UDP-[14C]GlcUA and the other
components described under "Experimental Procedures" for the assay
of HAS activity. The 14C-labeled HA products were then
recovered and analyzed by agarose gel electrophoresis and
autoradiography as described under "Experimental Procedures." The
molecular mass markers used were the indicated DNA fragments of defined
length (kilobase (kb)). A 7-kilobase DNA fragment
corresponds to an HA molecular weight of ~106 (32). SeHAS
variants shown are as follows. A: lane 1, C226A;
lane 2, C262A; lane 3, C281A; lane 4,
C367A; lane 5, wild-type; lane 6, C226S;
lane 7, C262S; lane 8, C281S; lane 9,
C367S. B: lane 1, C226A,C262A; lane 2,
C226A,C281A; lane 3, C226A,C367A; lane 4,
C262A,C281A; lane 5, C262A,C367A; lane 6,
C281A,C367A; lane 7, wild-type; lane 8,
( 3C)C262; lane 9, ( 3C)C281;
lane 10, ( 3C)C367; lane 11,
seHAScys-null; lane 12,
( 3C)C226.
|
|
Assessment of Disulfide Bond Formation in seHAS--
To understand
the potential role of Cys residues in the function of seHAS, it is
necessary to determine whether any of its four cysteines are involved
in the formation of disulfide bonds. We undertook two approaches to
answer this question. In the first approach, we treated E. coli membranes containing recombinant seHAS with
[14C]NEM to determine whether the wild-type or Cys mutant
seHAS proteins could be radiolabeled and then identified by
autoradiography after SDS-PAGE (Fig. 7).
We used this NEM reactivity to indicate the presence of free cysteines,
which are not involved in disulfide bond formation. Each of the six
Cys-to-Ala double Cys mutants of seHAS was radiolabeled by
[14C]NEM. The labeling was specific because the
vector-alone control and the Cys-null mutant did not show significant
labeling. These results indicate that none of the Cys residues in seHAS
are involved in disulfide bonds. A 31-kDa band, which was present in
the mixture of NEM-labeled proteins from the wild-type and several
double-Cys mutants, could be a degradation product of HAS, since it was
not present in the vector-alone controls. Such a fragment is expected to be inactive and illustrates the importance of normalizing the kinetic data to the amount of intact HAS protein, as assessed by
protein staining of SDS-PAGE gels (18).

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 7.
Reactivity of [14C]NEM with the
Cys-to-Ala double mutants of seHAS. E. coli membranes
containing wild-type (WT) or double Cys-mutants of seHAS
were incubated in two separate experiments (panels A and
B) with 2.5 mM [14C]NEM (8 × 106 dpm) at 4 °C for 10 min. The excess of
[14C]NEM was quenched by the addition of 40 mM DTE and incubation for 5 min at 4 °C. Trichloroacetic
acid was added to a final concentration of 10%, and the samples were
incubated at 4 °C overnight. The membrane pellet was washed by
centrifugation 3 times with 5% trichloroacetic acid, suspended in 20 µl of Laemmli sample buffer (33), and neutralized with sodium
hydroxide. The samples were heated at 95 °C for 3 min and subjected
to SDS-PAGE. The gels were processed and analyzed as described under
"Experimental Procedures."
|
|
In the second approach to assess the presence of disulfide bonds, we
treated the purified enzyme with biotin-PEO-maleimide, and the modified
protein products were then analyzed by MALDI-TOF mass spectrometry
(Fig. 8). For each biotin-PEO-maleimidyl
group added, the mass of the seHAS derivative would increase by 525.6 Da. The treated wild-type seHAS contained a distribution of derivatized products with increased masses equal to the addition of one-to-four biotin-PEO-maleimide groups per seHAS (Fig. 8A). Most of the
proteins were modified by the addition of 3 or 4 groups, demonstrating that the enzyme has no disulfide bonds. The observed mass values for
the three largest adducts differed from the predicted values by
<0.005%. The degree of modification was only slightly higher when the
wild-type seHAS was treated with biotin-PEO-maleimide in the presence
of 6 M guanidinium hydrochloride (not shown). This latter
result indicates that none of the four Cys residues is substantially
buried in the native enzyme; they are all accessible to react with the
relatively large modifying reagent. The seHASCys-null
protein was also treated with biotin-PEO-maleimide as a control to
verify that no derivatized enzyme products could be formed in the
absence of Cys groups (Fig. 8B). The result confirms that the modifying reagent does not react with any other amino acid side
chains and is specific for Cys; no covalent adducts were formed with
the Cys-null protein.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 8.
MALDI-TOF mass spectrographs of
seHAS-His6 derivatives covalently modified by a sulfhydryl
reagent. Wild-type seHAS-His6 (panel A) or
seHAS-His6Cys-null (panel B) were
incubated with (the upper traces in each panel)
or without (lower traces in each panel)
biotin-PEO-maleimide, and the eluted proteins were then prepared for
mass analysis as described under "Experimental Procedures." The
predicted mass-to-charge ratios for covalent adducts containing 2, 3, or 4 biotin-PEO-maleimide groups per wild-type enzyme molecule (in
parentheses), and the observed centroid mass-to-charge
ratios are indicated above the peaks. The predicted
m/z ratio for the (MH)+ ion of
unmodified seHASCys-null-His6 (with 4 Ala
residues replacing the four Cys residues) is 48,473.1.
|
|
 |
DISCUSSION |
The HAS enzymes are unique in that they polymerize two sugars,
GlcUA and GlcNAc, in an alternate fashion and simultaneously extrude
the growing HA chain through the plasma membrane (21, 23). The
streptococcal HASs are the smallest members of the Class I HAS family
and perform all the functions required for HA synthesis and secretion
from cells. Unlike the eukaryotic HAS enzymes, with which they share
substantial homology and probably an identical topological organization
in their common regions, the streptococcal enzymes have been easier to
study because they can be readily overexpressed, purified, and
characterized. To date, only one eukaryotic enzyme, mouse HAS1, has
been overexpressed, purified, and characterized kinetically (34). One
of our goals has been to understand how the Class I HAS enzymes
function by using the streptococcal enzymes as a model.
We initially focused on the importance of Cys residues in seHAS for
three reasons. First, Cys residues play important structural and
functional roles in many proteins (e.g. Ref. 35). Second, the four Cys residues in seHAS at positions 226, 262, 281, and 367 are
completely conserved in the two other streptococcal enzymes, Streptococcus uberis HAS and spHAS, and are generally
conserved in all the other eukaryotic HASs (Fig. 1). Finally,
p-chloromercurobenzoate had been reported to inhibit HA
biosynthesis by the Group A spHAS in a cell-free system (36). Although
no further studies on the role of sulfhydryls in HAS function had
appeared since that report, we decided to investigate the possibility
that Cys residues may be required for HAS activity.
Our present results demonstrate that a variety of sulfhydryl reagents
inhibit both the spHAS and seHAS enzymes. This inhibition could reflect
an important role of Cys in the function of these bacterial HAS
proteins. However, interpretation of these results is complicated by
the fact that Cys modification creates two changes in the enzyme; the
S-H group is eliminated, but a new S-R group is also introduced, where
R depends on the sulfhydryl reagent used. Because all the R groups are
larger than the initial H, modified Cys residues may create new steric
constraints for particular enzyme functions such as substrate binding.
Alternatively, different degrees of HAS inhibition by different
sulfhydryl reagents could indicate their different reactivity toward
Cys residues, which would depend upon their size, charge, or polarity.
The use of site-directed mutagenesis to alter the native Cys residues,
although subject to the same concerns noted above, provides a
complementary approach to determine the importance of Cys residues in
HAS function. Both approaches show that although HAS activity is
decreased by altering Cys residues, it is not eliminated; the
completely modified Cys-null enzyme was still able to perform all of
the functions needed for HA synthesis.
A fundamental question in the present study was whether seHAS contains
any disulfide bonds. We addressed this issue in two ways, by mass
spectrometric characterization of chemically modified, affinity-purified wild-type seHAS and also by the ability to radiolabel free Cys residues in each of the six double Cys-mutants of seHAS. Both
approaches demonstrated clearly that the seHAS enzyme does not contain
any disulfide bonds. It is reasonable to conclude, therefore, that the
streptococcal HAS proteins do not have disulfide bonds. It may be more
difficult to determine whether the eukaryotic HAS proteins contain
disulfide bonds, since these proteins are difficult to purify in high
yield (34) and contain more Cys residues (
14) than the streptococcal
proteins (21).
All HAS enzymes make a broad size range of HA rather than a discrete
size. This heterogeneity of product size may be important biologically
for particular functions of the three vertebrate HAS enzymes. In
addition, the HA size distribution made varies among the streptococcal
HASs (18) and also among the three mammalian HAS isoforms (37, 38).
These enzymatic differences in the size distribution of HA products,
which have only been observed in vitro (e.g. in
isolated cells or membrane preparations), could have very significant
biological consequences if they also occur in vivo in
various eukaryote cells and tissues. Numerous studies during the last
decade demonstrate that HA is not simply a structural component of the
extracellular matrices of most vertebrate tissues but also a cell
signaling molecule capable of modifying important aspects of cell
behavior including migration and adhesion (1, 2). The most interesting
and surprising aspect of this new paradigm regarding the biological
functions of HA is that many cells respond only if the HA is a specific
size (39). In particular, small oligosaccharides of HA have very
different biological activities than large, native-size HA.
An intriguing finding in the present study is that some, but not all,
combinations of Cys mutations in seHAS cause the enzyme to synthesize
smaller HA products. Eight of the 19 Cys mutants examined synthesized
HA with an apparently normal distribution of sizes that were shifted to
varying degrees to smaller masses. There was no apparent correlation
between changes in HA elongation rate (Vmax
values) and HA size distribution among these Cys mutants. The least
active seHAS variants nonetheless made HA products that were similar in
size to the HA made by the wild-type enzyme. We have not estimated the
average masses for the HA produced by the various mutants because the
agarose gel electrophoresis technique is more suitable for obtaining a
qualitative, rather than quantitative, assessment of size differences.
It is very difficult to assess the reliability of size assessments
outside the narrow range in which migration is proportional to size.
For example, several Cys mutants (e.g. one each of the
single, double, and triple mutants in Fig. 6) may actually synthesize
substantially larger HA than wild type, but the migration differences
compared with wild type are very small. For these reasons, we are just
beginning a study to characterize the HA size distributions of these
seHAS mutants using gel permeation chromatography coupled to dynamic
light scattering. Further studies will also be required to assess more
thoroughly any possible relationships between altered HA elongation
rates and HA product sizes in the Cys mutants presented here. Future studies will also assess the possibility that the functional
characteristics of some of the seHAS Cys mutants described here in
isolated membranes could be different after detergent solubilization.
Nonetheless, the present study demonstrates a role of Cys residues in
controlling HA chain length. In particular, the single Cys mutant C281A
makes much smaller HA, whereas the C281S mutant makes HA products very similar in size compared with wild-type seHAS.
Although NEM treatment of seHAS caused the velocity maximum
(Vmax) of the enzyme to decrease, it did not
substantially change the Km values for either
nucleotide-sugar compared with untreated seHAS. These results indicate
that the ability of the NEM-treated enzyme to bind each substrate is
not greatly decreased by modification of its Cys residues, but the
overall catalytic rate is slowed. In contrast, some of the
site-specific Cys mutants showed greater changes in their kinetic constants.
None of the single Cys-to-Ala or Cys-to-Ser mutants of seHAS are
inactive, indicating that no single Cys residue plays a critical, necessary role in HA synthesis. The specific HAS activity remaining in
the single, double, triple, and Cys-null mutants confirms that Cys is
not required at any position within the enzyme for a critical step in
HA synthesis. Nonetheless, Cys226 and Cys262
together appear to play an important role in the activity of seHAS,
since the double mutant seHAS(C226A,C262A) was the least active Cys
mutant, with only 2-3% wild-type activity. Despite its low activity,
this double mutant nonetheless synthesized HA of normal size. The
triple Cys-mutant seHAS(
3C)C281 also had very low
activity, similar to the double Cys-mutant seHAS(C226A,C262A), and also
synthesized normal size HA. These results indicate that alteration of
Cys367 has little or no affect on HAS activity and are
consistent with the single Cys mutant results in Table IV.
Interestingly, the lower functionality of seHAS(C226A, C262A)
was substantially relieved by the introduction of a C281A change to
create seHAS(
3C)C367 the triple Cys-mutant. Possibly a
structural or functional constraint, perhaps related to HA chain
length, brought about by mutating Cys226 and
Cys262 to Ala, is substantially relieved by simultaneously
mutating Cys281. The triple mutant
seHAS(
3C)C367 and the Cys-null mutant had similar
activities and HA product sizes, suggesting a similar degree of
compensation for the otherwise deleterious
Cys226/Cys262 double mutation. The Cys-null
mutant of seHAS retained ~20% of wild-type activity. The results
indicate that Cys226 and Cys262 play an
important role in the overall activity and kinetic characteristics of
seHAS, but Cys281 may play a role in regulating HA size.
Based on the recently determined topology of spHAS (22) and its high
level of homology with seHAS (72% identical plus 10% similar
residues), we know that Cys226, Cys262, and
Cys281 are present in the central domain region of seHAS
(Fig. 1), which is the region that contains
-glycosyltransferase
family motifs (40). The topological model predicts that
Cys367 is very close to transmembrane domain 4 and is
probably not near the glycosyl- transferase motifs.
Based on the NEM modification and Cys mutagenesis results, it appears
that one or more Cys residues may be located close to the
nucleotide-sugar binding sites of the seHAS enzyme. This possibility provides a rationale to explain why modification or alteration of these
Cys residues interferes with enzyme function and lowers enzyme
activity. Preliminary results from ongoing
studies2 suggest that either
substrate, UDP-GlcUA or UDP-GlcNAc, can protect seHAS from inhibition
by NEM, supporting the premise that at least one Cys residue is located
in or near a nucleotide-sugar binding pocket. Substrate binding to this
site appears to interfere with the reaction between NEM and the nearby
Cys residue(s). Similar conclusions about the proximity of Cys residues
to substrate binding sites have been reported for several other
proteins, including the lactose permease (41), glutathione synthetase
(42), glucocorticoid receptor (43), retinoic acid receptor
(44),
and plasma membrane proton-ATPase (45). All of these studies found that
modification of Cys residues by sulfhydryl reagents decreased the
activity of the protein, even though Cys mutagenesis did not inactivate the protein. Another recent study generated 400 Cys-scanning mutants of
a tetracycline transporter to map the membrane topology and active site
of the protein in membrane preparations (46). The ability of
tetracycline to protect only particular Cys residues from reaction with
NEM and subsequent inactivation of the protein allowed the tetracycline
binding site and channel to be mapped.
The creation of a seHASCys-null mutant that retains
enzymatic activity may allow us to examine in more depth the tertiary
structure of the enzyme and conformational changes that might occur
during substrate binding, catalysis, or HA translocation. To understand these processes, one must determine the interactions and proximity of
various domains within the protein. Cys-scanning mutants (47) of seHAS
containing a single unique Cys residue at a desired position could
allow us to employ electron paramagnetic resonance studies by modifying
this Cys residue with a suitable probe. This approach, for example,
allowed Voss et al. (48) to determine the proximity of that
modified residue to another region of the Lac permease. Similarly, one
can chemically modify a single unique Cys residue with a fluorescent
probe and systematically analyze the local environment in different
regions of the protein (49). Interacting or proximal domains within
seHAS may also be determined by assessing the formation of disulfide
bonds in specific mutants containing two Cys residues (50). Such
approaches may help elucidate the structure and function of seHAS and
increase our understanding of how the HAS family is able to synthesize
HA.
 |
ACKNOWLEDGEMENTS |
We thank Anil Singh for technical assistance
and Leona Medved for assistance with the manuscript. We also thank Lia
Kaupp and Christina A. Baron for assistance with the kinetic assays.
 |
FOOTNOTES |
*
This research was supported by NIGMS, National Institutes of
Health Grant GM35978.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.: 405-271-1288;
Fax: 405-271-3092; E-mail: paul-weigel@ouhsc.edu.
Published, JBC Papers in Press, January 17, 2002, DOI 10.1074/jbc.M110638200
2
K. Kumari, V. L. Tlapak-Simmons, and
P. H. Weigel, manuscript in preparation.
 |
ABBREVIATIONS |
The abbreviations used are:
HAS, HA synthase;
HA, hyaluronan or hyaluronic acid;
GlcUA, glucuronic acid;
biotin-PEO-maleimide, (+)-biotinyl-3-maleimidopropionamidyl-3,6-dioxaoctanediamine;
DTE, dithioerythritol;
NEM, N-ethylmaleimide;
PBS, phosphate-buffered saline;
seHAS, S. equisimilis HAS;
spHAS, S. pyogenes HAS;
MALDI-TOF, matrix-assisted laser
desorption ionization/time of flight.
 |
REFERENCES |
| 1.
|
Laurent, T. C.,
and Fraser, J. R. E.
(1992)
FASEB J.
6,
2397-2404[Abstract]
|
| 2.
|
Toole, B. P.
(1997)
J. Intern. Med.
242,
35-40[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Abatangelo, G., and Weigel, P. H.
(eds)
(2000)
New Frontiers in Medical Sciences: Redefining Hyaluronan
, Elsevier Science Publishers B. V., Amsterdam
|
| 4.
|
Knudson, C. B.,
and Knudson, W.
(1993)
FASEB J.
7,
1233-1241[Abstract]
|
| 5.
|
Fenderson, B. A.,
Stamenkovic, I.,
and Aruffo, A.
(1993)
Differentiation
54,
85-98[Medline]
[Order article via Infotrieve]
|
| 6.
|
Wessels, M. R.,
Goldberg, J. B.,
Moses, A. E.,
and Dicesare, T. J.
(1994)
Infect. Immun.
62,
433-441[Abstract/Free Full Text]
|
| 7.
|
Kass, E. H.,
and Seastone, C. V.
(1944)
J. Exp. Med.
79,
319-330[Abstract]
|
| 8.
|
DeAngelis, P. L.,
Papaconstantinou, J.,
and Weigel, P. H.
(1993)
J. Biol. Chem.
268,
19181-19184[Abstract/Free Full Text]
|
| 9.
|
Spicer, A. P.,
and McDonald, J. A.
(1998)
J. Biol. Chem.
273,
1923-1932[Abstract/Free Full Text]
|
| 10.
|
Itano, N.,
and Kimata, K.
(1996a)
J. Biol. Chem.
271,
9875-9878[Abstract/Free Full Text]
|
| 11.
|
Shyjan, A. M.,
Heldin, P.,
Butcher, E. C.,
Yoshino, T.,
and Briskin, M. J.
(1996)
J. Biol. Chem.
271,
23395-23399[Abstract/Free Full Text]
|
| 12.
|
Spicer, A. P.,
Augustine, M. L.,
and McDonald, J. A.
(1996)
J. Biol. Chem.
271,
23400-23406[Abstract/Free Full Text]
|
| 13.
|
Watanabe, K.,
and Yamaguchi, Y.
(1996)
J. Biol. Chem.
271,
22945-22948[Abstract/Free Full Text]
|
| 14.
|
DeAngelis, P. L.
(1999)
Cell. Mol. Life Sci.
56,
670-682[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Usui, T.,
Suzuki, K.,
Kaji, Y.,
Amano, S.,
Miyata, K.,
Heldin, P.,
and Yamashita, H.
(1999)
Investig. Ophthalmol. Vis. Sci.
40,
563-567[Abstract/Free Full Text]
|
| 16.
|
Ohno, S.,
Tanimoto, K.,
Fujimoto, K.,
Ijuin, C.,
Honda, K.,
Tanaka, N.,
Doi, T.,
Nakaharra, M.,
and Tanne, K.
(2001)
Biochim. Biophys Acta
1520,
71-78[Medline]
[Order article via Infotrieve]
|
| 17.
|
DeAngelis, P. L.,
Jing, W.,
Graves, M. V.,
Burbank, D. E.,
and Van Etten, J. L.
(1997)
Science
278,
1800-1803[Abstract/Free Full Text]
|
| 18.
|
Kumari, K.,
and Weigel, P. H.
(1997)
J. Biol. Chem.
272,
32539-32546[Abstract/Free Full Text]
|
| 19.
|
Ward, P. N.,
Field, T. R.,
Ditcham, W. G.,
Maguin, E.,
and Leigh, J. A.
(2001)
Infect. Immun.
69,
392-399[Abstract/Free Full Text]
|
| 20.
|
DeAngelis, P. L.,
Jing, W.,
Drake, R. R.,
and Achyuthan, A. M.
(1998)
J. Biol. Chem.
273,
8454-8458[Abstract/Free Full Text]
|
| 21.
|
Weigel, P. H.,
Hascall, V. C.,
and Tammi, M.
(1997)
J. Biol. Chem.
272,
13997-14000[Free Full Text]
|
| 22.
|
Heldermon, C. D.,
DeAngelis, P. L.,
and Weigel, P. H.
(2001)
J. Biol. Chem.
276,
2037-2046[Abstract/Free Full Text]
|
| 23.
| Weigel, P. H. (1998) in Science of Hyaluronan Today
(Hascall, V. C., and Yanagishita, M., eds) Chapter 7, www.GlycoForum.gr.jp
|
| 24.
|
Tlapak-Simmons, V. L.,
Baggenstoss, B., A.,
Kumari, K.,
Heldermon, C.,
and Weigel, P. H.
(1999)
J. Biol. Chem.
274,
4246-4253[Abstract/Free Full Text]
|
| 25.
|
Philipson, L. H.,
and Schwartz, N. B.
(1984)
J. Biol. Chem.
259,
5017-5023[Abstract/Free Full Text]
|
| 26.
|
Prehm, P.
(1984)
Biochem. J.
220,
597-600[Medline]
[Order article via Infotrieve]
|
| 27.
|
Tlapak-Simmons, V. L.,
Baggenstoss, B. A.,
Clyne, T.,
and Weigel, P. H.
(1999)
J. Biol. Chem.
274,
4239-4245[Abstract/Free Full Text]
|
| 28.
|
Ito, K.,
Sato, T.,
and Yura, T.
(1977)
Cell
11,
551-559[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Michaelis, L.,
and Menten, M. L.
(1913)
Biochem. Z.
49,
333-338
|
| 30.
|
Hill, A. V.
(1913)
Biochem. J.
7,
471-480
|
| 31.
|
Bradford, M. M.
(1976)
Anal. Biochem.
72,
248-254[CrossRef][Medline]
[Order article via Infotrieve]
|
| < |